Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Novartis (NVS) settling at $107.45, representing a -0.14% change from its previous close.
Novartis AG (NVS) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
Novartis AG (NVS) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
Novartis CEO Vasant Narasimhan: The right story for the company was to focus on R&D
Novartis CEO Vasant Narasimhan joins 'Money Movers' to discuss the company's overall M&A strategy, the businesses that Narasimhan wanted to get out of, and how big the Entresto drug can be.
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. NASDAQ: VYGR is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with Nov...
Novartis (NVS) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Novartis (NVS) closed at $106.31, indicating a +0.7% shift from the previous trading day.
Voyager Therapeutics' Novartis deal has analysts bullish on stock's long-term outlook
Voyager Therapeutics' announcement that it has entered into an additional up to $1.2 billion collaboration with Novartis AG (ADR) (NYSE:NVS) for its TRACER capsids to develop potential gene therapi...
Voyager Therapeutics and Novartis Sign Deal for Neurological Disease Treatments
Shares of Voyager Therapeutics Inc. (VYGR) jumped Tuesday after the biotech firm agreed to a strategic collaboration and capsid licensing agreement with Novartis AG (NVS) to treat neurological illn...
Voyager Therapeutics shares pop on collaboration with Novartis worth up to $1.2B
Voyager Therapeutics Inc (NASDAQ:VYGR) shares rallied more than 30% in Tuesday pre-market trading after the company announced a strategic collaboration and capsid license agreement worth up to $1.2...
Novartis (NVS) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Novartis (NVS) closed at $98.87, indicating a -0.84% shift from the previous trading day.
Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.
Novartis aims for 5% annual sales growth through 2027
Novartis said it was targeting annual sales growth of 5% per year until 2027 and a core operating income margin of about 40% by 2027, driven by innovative drugs on the market, after it severed owne...
Novartis AG (NVS) 10th Annual ESG Investor Event Conference (Transcript)
Novartis AG (NYSE:NVS ) 10th Annual ESG Investor Event Conference November 13, 2023 10:30 AM ET Company Participants Maria Victoria Cuevas - IR Vas Narasimhan - CEO Lutz Hegemann - President, Globa...
Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028
Sandoz is a global leader in the generics and biosimilars sector, with a strong position in the off-patent medicines market. The company recently listed and plans to aggressively pursue a slice of ...
Novartis says drug candidate is successful in rare kidney disease trial
Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage d...
New And Improved Novartis
Novartis recently completed the spin-off of Sandoz, which improved its growth and margin profile. The biopharma business is in good shape, with a decent collection of high-growth products and pipel...
Related Companies